Key points from article :
Cytomos, a biotechnology company based in Edinburgh, has raised £5 million to expand its operations and cell analysis technology. The funding round was led by Archangels, with additional support from Old College Capital, Scottish Enterprise, and the British Business Bank. This investment will drive the commercial rollout of Celledonia, a bench-top cell analyzer developed using the company’s AuraCyt platform. Celledonia offers a scalable, cost-effective solution for single-cell analysis, which plays a crucial role in biological drug discovery, development, and biologics manufacturing.
Cytomos currently employs 21 staff at its facility in Roslin and plans to add four more employees over the next year as part of its growth strategy. The company is also preparing to establish a presence in North America, with plans for trials in collaboration with global partners and interest from a leading pharmaceutical company.
The AuraCyt platform addresses key challenges in developing cell-derived medicines, which are typically expensive and complex to produce. By enabling real-time monitoring and prediction of cell parameters, the technology reduces costs and accelerates timelines, helping biopharma companies bring therapies to market up to six months faster. This is particularly valuable as the industry faces increasing pressure to develop therapies more efficiently.
Cytomos’ chief executive described the £5 million funding as a significant milestone, highlighting the team’s achievements in launching their first commercial product. He emphasized the company’s readiness to scale operations and expand into international markets. Sarah Hardy of Archangels praised Cytomos’ progress, noting their successful commercialization and plans to secure a robust supply chain.
With its innovative technology and a strong foundation for growth, Cytomos aims to advance the automation of biological drug development and establish itself as a leader in the biopharma industry.
